For the year ending 2025-12-31, RNTX had -$9,650K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -49,871 |
| Commitment fee related to pre-paid advance agreement | 300 |
| Original issue discount related to pre-paid advance agreement | 150 |
| Depreciation and amortization expense | 1 |
| Stock-based compensation expense | 2,224 |
| Impairment loss on intangible assets | 28,700 |
| Prepaid expenses and other current assets | 319 |
| Other assets | 0 |
| Accounts payable | 3,065 |
| Operating lease liabilities | 0 |
| Accrued expenses and other current liabilities | -2,622 |
| Other long-term liabilities | -277 |
| Deferred tax liabilities | -712 |
| Net cash used in operating activities | -19,361 |
| Proceeds from issuance of common stock, net of offering costs | 1,819 |
| Proceeds from pre-paid advances, net of discounts | 2,850 |
| Proceeds from issuance of common stock in connection with stock option exercises | 4 |
| Proceeds from issuance of common stock in connection with warrant exercises, net of costs | 1,595 |
| Proceeds from issuance of warrants, net of offering costs | 481 |
| Proceeds from warrant exchanges, net of offering costs | 2,984 |
| Proceeds from warrant exercises with common stock subscribed | 22 |
| Net cash provided by financing activities | 9,755 |
| Effect of exchange rate changes on cash and cash equivalents | -44 |
| Net decrease in cash and cash equivalents | -9,650 |
| Cash and cash equivalents at beginning of year | 12,865 |
| Cash and cash equivalents at end of year | 3,215 |
Rein Therapeutics, Inc. (RNTX)
Rein Therapeutics, Inc. (RNTX)